Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 301

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Open access
Eberlein, Catherine A., Stetson, Daniel, Markovets, Aleksandra A., Al-Kadhimi, Katherine J., Lai, Zhongwu, Fisher, Paul R., Meador, Catherine B., Spitzler, Paula, Ichihara, Eiki, Ross, Sarah J., Ahdesmaki, Miika J., Ahmed, Ambar, Ratcliffe, Laura E., O'Brien, Elizabeth L. Christey, Barnes, Claire H., Brown, Henry, Smith, Paul D., Dry, Jonathan R., Beran, Garry, Thress, Kenneth S., Dougherty, Brian, Pao, William, Cross, Darren A.E.·2015·Cancer Research

Abstract

Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells (PC9 and/or NCI-H1975) with acquired resistance to current and newly developed EGFR tyrosine kinase inhibitors, including AZD9291. We report the detection of NRAS mutations, including a novel E63K mutation, and a gain of copy number of WT NRAS or WT KRAS in cell populations resistant to gefitinib, afatinib, WZ4002, or AZD9291. Compared with parental cells, a number of resistant cell populations were more sensitive to inhibition by the MEK inhibitor selumetinib (AZD6244; ARRY-142886) when treated in combination with the originating EGFR inhibitor. In vitro, a combination of AZD9291 with selumetinib prevented emergence of resistance in PC9 cells and delayed resistance in NCI-H1975 cells. In vivo, concomitant dosing of AZD9291 with selumetinib caused regression of AZD9291-resistant tumors in an EGFRm/T790M transgenic model. Our data support the use of a combination of AZD9291 with a MEK inhibitor to delay or prevent resistance to AZD9291 in EGFRm and/or EGFRm/T790M tumors. Furthermore, these findings suggest that NRAS modifications in tumor samples from patients who have progressed on current or EGFR inhibitors in development may support subsequent treatment with a combination of EGFR and MEK inhibition. Cancer Res; 75(12); 2489–500. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-3167

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 301

Metadata

Authors
Eberlein, C. A., Stetson, D., Markovets, A. A., Al-Kadhimi, K. J., Lai, Z., Fisher, P. R., Meador, C. B., Spitzler, P., Ichihara, E., Ross, S. J., Ahdesmaki, M. J., Ahmed, A., Ratcliffe, L. E., O'Brien, E. L. C., Barnes, C. H., Brown, H., Smith, P. D., Dry, J. R., Beran, G., Thress, K. S., Dougherty, B., Pao, W., & Cross, D. A. E.
Venue
Cancer Research
Published
2015-06-14
Volume
75
Issue
12
Pages
2489-2500
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2050211354
Cited by
301
References
39
FWCI
29.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-3167
The paper
Eberlein, C. A., Stetson, D., Markovets, A. A., Al-Kadhimi, K. J., Lai, Z., Fisher, P. R., Meador, C. B., Spitzler, P., Ichihara, E., Ross, S. J., Ahdesmaki, M. J., Ahmed, A., Ratcliffe, L. E., O'Brien, E. L. C., Barnes, C. H., Brown, H., Smith, P. D., Dry, J. R., Beran, G., . . . Cross, D. A. E. (2015). Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-3167

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.